Cargando…

Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance

Type 2 diabetes mellitus (T2DM) increases morbimortality in humans via enhanced susceptibility to cardiovascular disease (CVD). Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are drugs designed for T2DM treatment to diminish hyperglycaemia by reducing up to 90% of renal tube glucose reabsorptio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taberner-Cortés, Alida, Vinué, Ángela, Herrero-Cervera, Andrea, Aguilar-Ballester, María, Real, José Tomás, Burks, Deborah Jane, Martínez-Hervás, Sergio, González-Navarro, Herminia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730942/ https://www.ncbi.nlm.nih.gov/pubmed/33287201 http://dx.doi.org/10.3390/ijms21239216

Ejemplares similares

Impact of Cholesterol Metabolism in Immune Cell Function and Atherosclerosis
por: Aguilar-Ballester, María, et al.
Publicado: (2020)

Type 1 diabetic mellitus patients with increased atherosclerosis risk display decreased CDKN2A/2B/2BAS gene expression in leukocytes
por: Martínez-Hervás, Sergio, et al.
Publicado: (2019)

Dissecting Abdominal Aortic Aneurysm Is Aggravated by Genetic Inactivation of LIGHT (TNFSF14)
por: Herrero-Cervera, Andrea, et al.
Publicado: (2021)

Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia
por: Aguilar-Ballester, María, et al.
Publicado: (2021)

Understanding the Impact of Dietary Cholesterol on Chronic Metabolic Diseases through Studies in Rodent Models
por: Vinué, Ángela, et al.
Publicado: (2018)

Srebf2 Locus Overexpression Reduces Body Weight, Total Cholesterol and Glucose Levels in Mice Fed with Two Different Diets
por: Andrés-Blasco, Irene, et al.
Publicado: (2020)

Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists
por: Jiménez-Martí, Elena, et al.
Publicado: (2022)

Unsaturated Oral Fat Load Test Improves Glycemia, Insulinemia and Oxidative Stress Status in Nondiabetic Subjects with Abdominal Obesity
por: Martinez-Hervas, Sergio, et al.
Publicado: (2016)

Effıcacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin
por: Sertbas, Meltem, et al.
Publicado: (2019)

Dapagliflozin's effect on serum homocysteine in patients with hypertension complicated with insulin resistance
por: Yu, Xiaoqian, et al.
Publicado: (2023)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
por: Tamez, Hector E., et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes
por: Watada, Hirotaka, et al.
Publicado: (2018)

Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial
por: Sorice, Gian Pio, et al.
Publicado: (2021)

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE(−/−) Mice
por: Leng, Weiling, et al.
Publicado: (2016)

Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials
por: Wu, Qian-Long, et al.
Publicado: (2022)

Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes
por: SAYED, Noha, et al.
Publicado: (2020)

Dapagliflozin: an effective adjunctive treatment in type 1 diabetes
por: Yadegarfar, Ghasem, et al.
Publicado: (2021)

Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
por: Han, Eugene, et al.
Publicado: (2018)

TET2-Loss-of-Function-Driven Clonal Hematopoiesis Exacerbates Experimental Insulin Resistance in Aging and Obesity
por: Fuster, José J., et al.
Publicado: (2020)

Not so critical appraisal of dapagliflozin
por: Doggrell, Sheila A
Publicado: (2014)

Novel Immune Features of the Systemic Inflammation Associated with Primary Hypercholesterolemia: Changes in Cytokine/Chemokine Profile, Increased Platelet and Leukocyte Activation
por: Collado, Aida, et al.
Publicado: (2018)

Insulin Receptor Substrate 2 Is Required for Testicular Development
por: Griffeth, Richard J., et al.
Publicado: (2013)

Insulin dose reduction in dapagliflozin combination therapy for type 1 diabetes mellitus: the RISING-STAR study
por: Hamaguchi, Masahide, et al.
Publicado: (2022)

Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model
por: Sokolov, Victor, et al.
Publicado: (2023)

Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II
por: Torre, Enrico, et al.
Publicado: (2020)

Diabetes, Insulin Resistance and Atherosclerosis Surrogates in Patients With Coronary Atherosclerosis
por: Park, Hyun-Woong, et al.
Publicado: (2010)

Anthropometric Indicators as a Tool for Diagnosis of Obesity and Other Health Risk Factors: A Literature Review
por: Piqueras, Paola, et al.
Publicado: (2021)

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
por: Wilding, John P.H., et al.
Publicado: (2009)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

An exploration of the experience of dapagliflozin in clinical practice
por: Anitha, Anuba Paulvarnan, et al.
Publicado: (2022)

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment
por: van der Walt, J-S, et al.
Publicado: (2013)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes
por: Sosale, Bhavana, et al.
Publicado: (2016)

Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients
por: Sun, Yue, et al.
Publicado: (2020)

Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
por: Aberle, Jens, et al.
Publicado: (2020)

Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model
por: SAYED, Noha, et al.
Publicado: (2021)

A Possible Novel Effect for Dapagliflozin in the Management of Subcutaneous Insulin Resistance Syndrome: A Report of Two Cases
por: Sweis, Nabil W. G., et al.
Publicado: (2022)

Optimización de productos y procesos industriales /
por: Figuera Vinué, Pau
Publicado: (2006)

Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_133uk09hu2iqjk1na0ufnf1at4